MC1R is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-01. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
In some cases, certain device geometries are preferred, for example a flow focusing junction was used to encapsulate bacteria in agarose microparticles. Multiple emulsions are of interest for pharmaceutical and cosmetic applications and are formed using two consecutive flow focusing junctions. More complicated particles can also be synthesized such as Janus particles, which have surfaces with two or more distinct physical properties. Some examples of the increasing application of gel particles include drug delivery, biomedical applications, and tissue engineering, and many of these applications require monodisperse particles where a microfluidics-based approach is preferred. Bulk emulsification methods are still relevant, though, since not all applications require uniform microparticles. The future of microfluidic synthesis of gels may lie in developing techniques to create bulk amounts of these uniform particles in order to make them more commercially/industrially available. Recent developments in droplet microfluidics have also allowed for in situ synthesis of hydrogel fibers containing aqueous droplets with controlled morphology. Hydrogel fibers provide an intriguing option for biocompatible material for drug delivery and bioprinting of materials that can mimic the behavior of an extracellular matrix. This microfluidic method differs from the traditional wet-spinning synthesis route through the use of aqueous droplets in an immiscible oil stream rather than the extrusion of a bulk solution of the same composition mixed off site.
Very low voltages are inefficient since the lead wires would conduct too much heat away from the filament, so the practical lower limit for incandescent lamps is 1.5 volts. Very long filaments for high voltages are fragile, and lamp bases become more difficult to insulate, so lamps for illumination are not made with rated voltages over 300 volts. Some infrared heating elements are made for higher voltages, but these use tubular bulbs with widely separated terminals.
The citric acid cycle begins with the transfer of a two-carbon acetyl group from acetyl-CoA to the four-carbon acceptor compound (oxaloacetate) to form a six-carbon compound (citrate). The citrate then goes through a series of chemical transformations, losing two carboxyl groups as CO2. The carbons lost as CO2 originate from what was oxaloacetate, not directly from acetyl-CoA. The carbons donated by acetyl-CoA become part of the oxaloacetate carbon backbone after the first turn of the citric acid cycle. Loss of the acetyl-CoA-donated carbons as CO2 requires several turns of the citric acid cycle. However, because of the role of the citric acid cycle in anabolism, they might not be lost, since many citric acid cycle intermediates are also used as precursors for the biosynthesis of other molecules. Most of the electrons made available by the oxidative steps of the cycle are transferred to NAD+, forming NADH. For each acetyl group that enters the citric acid cycle, three molecules of NADH are produced. The citric acid cycle includes a series of redox reactions in mitochondria. In addition, electrons from the succinate oxidation step are transferred first to the FAD cofactor of succinate dehydrogenase, reducing it to FADH2, and eventually to ubiquinone (Q) in the mitochondrial membrane, reducing it to ubiquinol (QH2) which is a substrate of the electron transfer chain at the level of Complex III. For every NADH and FADH2 that are produced in the citric acid cycle, 2.5 and 1.5 ATP molecules are generated in oxidative phosphorylation, respectively.
Sources: en.wikipedia.org
Affinity monolith chromatography provides another approach to drug response measurements. David Hage at the University of Nebraska–Lincoln binds ligands to monolithic supports and measures the equilibrium phenomena of binding interactions between drugs and serum proteins. A monolith-based approach at the University of Bologna, Italy, is currently in use for high-speed screening of drug candidates in the treatment of Alzheimer's. In 2003, Regnier and Liu of Purdue University described a multi-dimensional LC procedure for identifying single nucleotide polymorphisms (SNPs) in proteins. SNPs are alterations in the genetic code that can sometimes cause changes in protein conformation, as is the case with sickle cell anemia. Monoliths are particularly useful in these kinds of separations because of their superior mass transport capabilities, low backpressures coupled with faster flow rates, and relative ease of modification of the support surface. Bioseparations on a production scale are enhanced by monolith column technologies as well. The fast separations and high resolving power of monoliths for large molecules means that real-time analysis on production fermentors is possible.Fermentation is well known for its use in making alcoholic beverages, but is also an essential step in the production of vaccines for rabies and other viruses. Real-time, on-line analysis is critical for monitoring of production conditions, and adjustments can be made if necessary.
Narrated by Alun Lewis, directed by Gary Leach, produced by Geoff Deehan, produced by Sandlin Productions 24 November The Dyslexic Engineer, about Ben Bowlby, born on 2 November 1966; his VS91 car at Snetterton Circuit, with a Vauxhall Astra engine, with footage mostly from the end of the earlier documentary in September 1990; his studies at the Polytechnic of East London; Richard Bowlby, his father from Hampstead, who also realised that he was dyslexic; Rosalind Rathouse, his former remedial teacher; Roy Greenfield, a retired maths teacher from King Alfred School, London, who believed that perhaps people would adapt to mathematics more if the subject was taught later in life, as people are often put off the subject at secondary school; Ben gained nine O-levels but couldn't acquire Mathematics A-level above grade E after, two attempts; Xenia Bowlby; his polytechnic course tutor, Alan Slawson, and limited-slip differentials; his car raced in the Clubman (racing car class); he was sponsored by Ripspeed clothing and Spax Performance shock absorbers; Eric Broadly of Lola Cars; he joined Lola Cars in October 1991; he had attempted to gain a place at Lancaster University to study Engineering; Mike Blanchet of Lola Cars; empirical research in designing and building motor racing cars; Mark Williams, head of Formula 3000 at Lola Cars. Narrated by Ian Holm, produced by Michael Proudfoot, directed by Patrick Uden, made by Uden Associates.
==== Mass spectrometry ==== Since alkanes have high ionization energies, their electron impact mass spectra show weak currents for their molecular ions. The fragmentation pattern can be difficult to interpret, but in the case of branched chain alkanes, the carbon chain is preferentially cleaved at tertiary or quaternary carbons due to the relative stability of the resulting free radicals. The mass spectra for straight-chain alkanes is illustrated by that for dodecane: the fragment resulting from the loss of a single methyl group (M − 15) is absent, fragments are more intense than the molecular ion and are spaced by intervals of 14 mass units, corresponding to loss of CH2 groups.
Sources: en.wikipedia.org
The plebiscite areas (German: Abstimmungsgebiete; French: zones du plébiscite) were placed under the authority of two Inter-Allied Commissions of five members, who were appointed by the Principal Allied and Associated Powers representing the League of Nations. British and Italian troops, under the command of the Commissions, arrived on and soon after 12 February 1920 after the regular German Reichswehr had previously left the plebiscite areas. The civil and municipal administration was continued by the existing German authorities, which were responsible to the Commissions for their duration. In accordance with Articles 94 to 97 of the Treaty of Versailles (section entitled "East Prussia"), the Marienwerder Plebiscite Area was formed of northeastern Marienwerder Government Region, based in Marienwerder in West Prussia, now Kwidzyn, which encompassed the districts of Marienwerder (east of the Vistula), Stuhm (based in Stuhm, now Sztum), Rosenberg (based in Rosenberg in West Prussia, now Susz) as well as parts of Marienburg in West Prussia (based in Marienburg in West Prussia, Malbork, part of the Danzig Government Region) east of the Nogat. The treaty defined the Allenstein Plebiscite Area as "The western and northern boundary of Allenstein Government Region to its junction with the boundary between the districts of Oletzko (based in Marggrabowa, now Olecko) and of Angerburg (based in Angerburg, now Węgorzewo).
ribonucleotide A nucleotide containing ribose as its pentose sugar component, and the monomeric subunit of ribonucleic acid (RNA) molecules. Ribonucleotides canonically incorporate any of four nitrogenous bases: adenine (A), guanine (G), cytosine (C), and uracil (U). Compare deoxyribonucleotide.
== Treatment == Acute hypoglycemia is reversed by raising the blood glucose. Glucagon should be injected intramuscularly or intravenously, or dextrose can be infused intravenously to raise the blood glucose. Oral administration of glucose can worsen the outcome, as more insulin is eventually produced. Most people recover fully even from severe hypoglycemia after the blood glucose is restored to normal. Recovery time varies from minutes to hours depending on the severity and duration of the hypoglycemia. Death or permanent brain damage resembling stroke can occur rarely as a result of severe hypoglycemia. See hypoglycemia for more on effects, recovery, and risks. Further therapy and prevention depends upon the specific cause. Most hypoglycemia due to excessive insulin occurs in people who take insulin for type 1 diabetes. Management of this hypoglycemia is sugar or starch by mouth (or in severe cases, an injection of glucagon or intravenous dextrose). When the glucose has been restored, recovery is usually complete. Prevention of further episodes consists of maintaining balance between insulin, food, and exercise. Management of hypoglycemia due to treatment of type 2 diabetes is similar, and the dose of the oral hypoglycemic agent may need to be reduced. Reversal and prevention of hypoglycemia is a major aspect of the management of type 1 diabetes. Hypoglycemia due to drug overdose or effect is supported with extra glucose until the drugs have been metabolized. The drug doses or combination often needs to be altered.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.